The bill
A bill to require a declassification review for intelligence relating to the COVID-19 pandemic, and for other purposes.
S. 3291, 119th Congress — read as touching Pharmaceuticals.
A bill to require a declassification review for intelligence relating to the COVID-19 pandemic, and for other purposes.
Bill ID: 119/s/3291
Last Updated: December 1, 2025
Sponsored by
Sen. Young, Todd [R-IN]
ID: Y000064
Follow the money
The sponsor
Sen. Young, Todd [R-IN]
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
$124,500 raised
20 itemised contributions to this sponsor, pulled from FEC filings.
Bill's Journey to Becoming a Law
Track this bill's progress through the legislative process
Latest Action
Invalid Date
Introduced
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
🏛️
Committee Review
🗳️
Floor Action
✅
Passed Senate
🏛️
House Review
🎉
Passed Congress
🖊️
Presidential Action
⚖️
Became Law
📚 How does a bill become a law?
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Bill Summary
No summary available
💰 Campaign Finance Network
Sen. Young, Todd [R-IN]
Congress 119 • 2024 Election Cycle
Total Contributions
$124,500
20 donors
PACs
$0
Organizations
$0
Committees
$0
Individuals
$124,500
No PAC contributions found
No organization contributions found
No committee contributions found
1
HESS, DANIEL L.
$10,000
2
SHUBLAK, MARK I.
$6,600
3
MCLEAN, SUZZY
$6,600
4
MCLEAN, TERRENCE
$6,600
5
BESSENT, SCOTT K.
$6,600
6
PATRICELLI, ROBERT E.
$6,600
7
ANDREESSEN, MARC L.
$6,600
8
BRALY, DOUGLAS A. MR.
$6,600
9
DIXON, CHRISTOPHER
$6,600
10
HESS, LEANNA
$6,600
11
HOROWITZ, BEN
$6,600
12
MANDELBLATT, DANIELLE
$6,600
13
MANDELBLATT, ERIC
$6,600
14
ANDREESSEN, LAURA ARRILLAGA
$5,100
15
HOROWITZ, FELICIA
$5,100
16
SILENOK, ELENA
$5,100
17
SIMON, HERBERT MR.
$5,000
18
PAUGH, JOHN N. MR.
$5,000
19
PETRIE, MICHAEL F. MR.
$5,000
20
RICKER, JAY B. MR.
$5,000
Donor Network - Sen. Young, Todd [R-IN]
PACs
Organizations
Individuals
Politicians
Hub layout: Politicians in center, donors arranged by type in rings around them.
Loading...
Showing 51 nodes and 20 connections (48 secondary connections hidden)
Total contributions: $124,500
Top Donors - Sen. Young, Todd [R-IN]
Showing top 20 donors by contribution amount
20 Individuals
Industry Impact
Which industries are materially affected by specific provisions in this bill. 2 harmed.
- −Pharmaceuticalsconfidence 0.80
Section 2(b)(1)(C) and 2(b)(2)(F) imply that the bill may lead to increased scrutiny of pharmaceutical companies involved in Gain of Function research or development of COVID-19 medical interventions, potentially harming their business
- −Biotech & Researchconfidence 0.80
Section 2(b)(1)(C) and 2(b)(2)(F) suggest that biotech companies conducting research on coronaviruses or involved in Gain of Function research may face increased scrutiny, potentially harming their business
Who funds the sponsor on these industries
For each industry this bill affects, here's what the sponsor (Sen. Young, Todd [R-IN])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
Industries this bill HARMS
- Biotech & Research$1,500from 2 contributions
- EPPARD, JOHN W. MR.$1,500
- Pharmaceuticals$500from 1 contribution
- MILLER, PAULA$500